XTANDI — ASTELLAS, approved 2026-07-24 (NDA213674).
60,556 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.